Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006, 45: 529-538. 10.1016/j.jhep.2006.05.013.
Article
PubMed
Google Scholar
Ghany MG, Strader DB, Thomas DL, Seef IL: Diagnosis, management and treatment of hepatitis C: an update. Hepatology. 2009, 49: 1335-1374. 10.1002/hep.22759.
Article
CAS
PubMed
Google Scholar
Practice guidelines for the treatment of hepatitis C: Practice guidelines for the treatment of hepatitis C: Recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. Dig Liv Dis. 2010, 42: 81-91.
Article
Google Scholar
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001, 358: 958-965. 10.1016/S0140-6736(01)06102-5.
Article
CAS
PubMed
Google Scholar
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002, 347: 975-982. 10.1056/NEJMoa020047.
Article
CAS
PubMed
Google Scholar
Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM: PEGASYS International Study Group Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004, 140: 346-355.
Article
CAS
PubMed
Google Scholar
Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF: Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999, 354: 1896-1900. 10.1016/S0140-6736(99)04149-5.
Article
CAS
PubMed
Google Scholar
Jadad AR, Moore RA, Carrol D, Jenkinson C, Reynolds DJM, Gavalghon DJ: Assessing the quality of reports of randomized clinical trials. Is blinding necessary?. Control Clin Trials. 1996, 17: 1-12. 10.1016/0197-2456(95)00134-4.
Article
CAS
PubMed
Google Scholar
Chalmers TC, Smith H, Blackburn B, Silverman B, Schroeder B, Reitman D: A method for assessing the quality of a randomized control trial. Control Clin Trials. 1981, 2: 31-49. 10.1016/0197-2456(81)90056-8.
Article
CAS
PubMed
Google Scholar
Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959, 22: 719-748.
CAS
PubMed
Google Scholar
Der Simonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials. 1986, 7: 177-188. 10.1016/0197-2456(86)90046-2.
Article
CAS
Google Scholar
Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med. 2002, 21: 1539-1558. 10.1002/sim.1186.
Article
PubMed
Google Scholar
Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994, 50: 1088-1099. 10.2307/2533446.
Article
CAS
PubMed
Google Scholar
Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315: 629-634. 10.1136/bmj.315.7109.629.
Article
CAS
PubMed
PubMed Central
Google Scholar
Corporation S: Stata Statistical Software: Release 10. 2010, TX, USA: College Station
Google Scholar
Yenice N, Mehtap O, Gumrah M, Arican N: The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turk J Gastroenterol. 2006, 17: 94-98.
PubMed
Google Scholar
Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK: Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Vir Hep. 2007, 14: 721-729.
CAS
Google Scholar
Escudero A, Rodríguez F, Serra MA, Del Olmo JA, Montes F, Rodrigo JM: Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. J Gastroenterol Hepatol. 2008, 23: 861-866. 10.1111/j.1440-1746.2008.05397.x.
Article
CAS
PubMed
Google Scholar
McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS: IDEAL Study Team Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009, 361: 580-593. 10.1056/NEJMoa0808010.
Article
CAS
PubMed
Google Scholar
Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, Picciotto FP, Marino-Marsilia G, Fontanella L, Leandro G: Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology. 2010, 138: 116-122. 10.1053/j.gastro.2009.10.005.
Article
CAS
PubMed
Google Scholar
Lee S, Kim IH, Kim SH, Kim SW, Lee SO, Lee ST, Kim DG, Lee CS, Choi CS, Cho EY, Kim HC: Efficacy and tolerability of pegylated interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in treatment-naive chronic hepatitis C patients. Intervirology. 2010, 53: 146-153. 10.1159/000274975.
Article
CAS
PubMed
Google Scholar
Rumi MG, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Soffredini R, Del Ninno E, Russo A, Colombo M: Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology. 2010, 138: 108-115. 10.1053/j.gastro.2009.08.071.
Article
CAS
PubMed
Google Scholar
Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Abergel A, Pessôa MG, Lin A, Tietz A, Connell EV, Diago M: A Sustained Virologic Response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology. 2010, 139: 1593-1601. 10.1053/j.gastro.2010.07.009.
Article
CAS
PubMed
Google Scholar
Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C: Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology. 2010, 51: 1176-1184. 10.1002/hep.23504.
Article
CAS
PubMed
Google Scholar
Zhao S, Liu E, Chen P, Cheng D, Lu S, Yu Q, Wang Y, Wei K, Yang P: A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: a meta-analysis of randomized trials. Clin Ther. 2010, 32: 1565-1577. 10.1016/j.clinthera.2010.08.009.
Article
CAS
PubMed
Google Scholar
Taliani G, Gemignani G, Ferrari C, Aceti A, Bartolozzi D, Blanc PL, Capanni M, Esperti F, Forte P, Guadagnino V, Mari T, Marino N, Milani S, Pasquazzi C, Rosina F, Tacconi D, Toti M, Zignego AL, Messerini L, Stroffolini T: Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology. 2006, 130: 1098-1106. 10.1053/j.gastro.2006.02.016.
Article
CAS
PubMed
Google Scholar
Torriani FJ, Rodriguez-Torris M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV infected patients. N Engl J Med. 2004, 351: 438-450. 10.1056/NEJMoa040842.
Article
CAS
PubMed
Google Scholar
Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C: Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004, 351: 451-459. 10.1056/NEJMoa032653.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hiramatsu N, Oze T, Yakushijin T, Inoue Y, Igura T, Mochizukiet K, Imanaka K, Kaneko A, Oshita M, Hagiwara H, Mita E, Nagase T, Ito T, Inui Y, Hijioka T, Katayama K, Tamura S, Yoshihara H, Imai Y, Kato M, Yoshida Y, Tatsumi T, Ohkawa K, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N: Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin. J Vir Hep. 2009, 16: 586-594. 10.1111/j.1365-2893.2009.01106.x.
Article
CAS
Google Scholar
Jacobson IM, Brown RS, Freilich B, Afdhal N, Kwo PY, Santoro Y, Hargrave T, Kwo PY, Lambiase L, Galler GW, Araya V, Freilich B, Harvey J, Griffel LH, Brass CA: Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic Hepatitis C patients: a randomized trial. Hepatology. 2007, 46: 971-981. 10.1002/hep.21932.
Article
CAS
PubMed
Google Scholar